Patent ID: 9676839
Date: 2017-06-13
CPC Classifications: A61K,A61P,C07K

Claim:
1. A process of improving a monoclonal antibody's ability to inhibit the binding of a transmembrane receptor to its ligand, wherein said antibody comprises a hinge region, or of a divalent functional fragment of said antibody comprising a hinge region, wherein said process comprises: modifying an antibody that is capable of inhibiting the binding of a transmembrane receptor to its ligand by deleting, adding, or substituting at least one amino acid in the amino acid sequence of said hinge region of said antibody; selecting the modified antibody wherein the modification improves the antibody's ability to inhibit the binding of the transmembrane receptor to its ligand over a modified antibody wherein the modification does not improve the antibody's ability to inhibit the binding of the transmembrane receptor to its ligand; wherein the hinge that comprises a modification that improves the antibody's ability to inhibit the binding of the transmembrane receptor to its ligand; comprises SEQ ID No. 6.